Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V9BD
|
|||
| Former ID |
DAP000092
|
|||
| Drug Name |
Bicalutamide
|
|||
| Synonyms |
Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Approved | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
AstraZeneca plc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H14F4N2O4S
|
|||
| Canonical SMILES |
CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
|
|||
| InChI |
1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
|
|||
| InChIKey |
LKJPYSCBVHEWIU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 90357-06-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10360, 536636, 4422035, 7848024, 7978493, 8151593, 11528703, 12014029, 14807515, 26719836, 29221542, 46386630, 46505386, 46518598, 49681685, 49835627, 50113021, 50709017, 53790604, 57321290, 85174226, 85174230, 90341766, 91610973, 92308263, 92308948, 92711409, 93815120, 99016301, 99437214, 103164349, 104300407, 118046574, 121362017, 124658945, 124757067, 124800143, 124893438, 125163871, 125338410, 125359510, 125545351, 126630887, 126657361, 126665838, 128501765, 131295154, 134358448, 135014383, 135649993
|
|||
| ChEBI ID |
CHEBI:91617
|
|||
| ADReCS Drug ID | BADD_D00271 | |||
| SuperDrug ATC ID |
L02BB03
|
|||
| SuperDrug CAS ID |
cas=090357065
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Bicalutamide can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.612; p = 0.003). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Bicalutamide can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.493; p = 0.038). | |||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2863). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11. | |||
| REF 5 | Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.